Vanessa Leigh Merker, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neurofibromatoses | 29 | 2023 | 299 | 7.020 |
Why?
|
Neurilemmoma | 21 | 2023 | 547 | 5.020 |
Why?
|
Neurofibromatosis 1 | 20 | 2023 | 569 | 4.150 |
Why?
|
Neurofibromatosis 2 | 21 | 2023 | 380 | 4.010 |
Why?
|
Skin Neoplasms | 22 | 2023 | 5686 | 1.920 |
Why?
|
Rare Diseases | 5 | 2022 | 553 | 1.310 |
Why?
|
Neurofibroma, Plexiform | 2 | 2023 | 71 | 1.110 |
Why?
|
Nerve Sheath Neoplasms | 3 | 2015 | 190 | 0.640 |
Why?
|
Down Syndrome | 2 | 2023 | 880 | 0.620 |
Why?
|
Patient Participation | 2 | 2022 | 1457 | 0.530 |
Why?
|
Current Procedural Terminology | 1 | 2015 | 92 | 0.490 |
Why?
|
Quality of Life | 12 | 2023 | 12804 | 0.470 |
Why?
|
Health Literacy | 2 | 2017 | 414 | 0.440 |
Why?
|
Tomography | 1 | 2015 | 390 | 0.440 |
Why?
|
Preimplantation Diagnosis | 1 | 2014 | 151 | 0.430 |
Why?
|
Radiography, Abdominal | 1 | 2015 | 537 | 0.400 |
Why?
|
Neurofibroma | 2 | 2022 | 106 | 0.400 |
Why?
|
Veterans | 2 | 2022 | 2519 | 0.400 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2015 | 397 | 0.390 |
Why?
|
Hearing Loss | 5 | 2021 | 765 | 0.380 |
Why?
|
Pelvis | 1 | 2015 | 730 | 0.370 |
Why?
|
Communication | 3 | 2021 | 3749 | 0.370 |
Why?
|
Neuroma, Acoustic | 6 | 2018 | 451 | 0.340 |
Why?
|
Pregnancy Outcome | 2 | 2015 | 2795 | 0.300 |
Why?
|
Ambulatory Care | 1 | 2018 | 2708 | 0.300 |
Why?
|
Angiogenesis Inhibitors | 5 | 2016 | 2038 | 0.250 |
Why?
|
Clinical Trials as Topic | 5 | 2023 | 7913 | 0.240 |
Why?
|
Pregnancy Complications | 2 | 2015 | 2861 | 0.230 |
Why?
|
Consensus | 4 | 2023 | 2959 | 0.230 |
Why?
|
Pain Measurement | 5 | 2022 | 3420 | 0.230 |
Why?
|
Young Adult | 19 | 2022 | 56430 | 0.210 |
Why?
|
Mind-Body Therapies | 2 | 2016 | 247 | 0.210 |
Why?
|
Self Report | 4 | 2021 | 3558 | 0.200 |
Why?
|
Persian Gulf Syndrome | 1 | 2021 | 45 | 0.190 |
Why?
|
Health Services Accessibility | 1 | 2018 | 5137 | 0.190 |
Why?
|
Health Services Research | 2 | 2022 | 1836 | 0.190 |
Why?
|
Tumor Burden | 4 | 2018 | 1915 | 0.190 |
Why?
|
Adolescent | 21 | 2023 | 85781 | 0.190 |
Why?
|
Adult | 33 | 2023 | 214055 | 0.190 |
Why?
|
Humans | 51 | 2023 | 744343 | 0.180 |
Why?
|
Hearing | 2 | 2021 | 482 | 0.180 |
Why?
|
Whole Body Imaging | 4 | 2018 | 280 | 0.180 |
Why?
|
Child | 15 | 2023 | 77709 | 0.160 |
Why?
|
Telemedicine | 3 | 2021 | 2872 | 0.160 |
Why?
|
Job Satisfaction | 1 | 2022 | 535 | 0.160 |
Why?
|
Focus Groups | 1 | 2023 | 1321 | 0.160 |
Why?
|
Organizations, Nonprofit | 1 | 2018 | 104 | 0.160 |
Why?
|
Stress, Psychological | 3 | 2021 | 4245 | 0.150 |
Why?
|
Deafness | 1 | 2021 | 458 | 0.150 |
Why?
|
Middle Aged | 25 | 2022 | 213383 | 0.140 |
Why?
|
Male | 31 | 2022 | 350118 | 0.140 |
Why?
|
Trust | 1 | 2020 | 505 | 0.140 |
Why?
|
Female | 30 | 2023 | 380194 | 0.130 |
Why?
|
Genes, Neurofibromatosis 1 | 1 | 2014 | 79 | 0.120 |
Why?
|
Anxiety | 2 | 2021 | 4297 | 0.120 |
Why?
|
Relaxation | 1 | 2014 | 50 | 0.120 |
Why?
|
United States | 7 | 2023 | 69872 | 0.120 |
Why?
|
von Hippel-Lindau Disease | 1 | 2015 | 152 | 0.120 |
Why?
|
Aged | 14 | 2023 | 163280 | 0.110 |
Why?
|
Automobile Driving | 1 | 2018 | 431 | 0.110 |
Why?
|
Spinal Cord Neoplasms | 1 | 2015 | 281 | 0.110 |
Why?
|
Germ-Line Mutation | 2 | 2018 | 1788 | 0.110 |
Why?
|
Psychotherapy, Group | 1 | 2016 | 406 | 0.110 |
Why?
|
Age Distribution | 1 | 2018 | 2902 | 0.110 |
Why?
|
Travel | 1 | 2018 | 788 | 0.110 |
Why?
|
Parents | 2 | 2023 | 3407 | 0.110 |
Why?
|
Ependymoma | 1 | 2015 | 334 | 0.100 |
Why?
|
Health Benefit Plans, Employee | 1 | 2015 | 332 | 0.100 |
Why?
|
S100 Proteins | 1 | 2012 | 259 | 0.100 |
Why?
|
Ambulatory Care Facilities | 1 | 2018 | 933 | 0.100 |
Why?
|
Osteoarthritis, Knee | 1 | 2022 | 1222 | 0.100 |
Why?
|
Qualitative Research | 1 | 2020 | 2682 | 0.100 |
Why?
|
Live Birth | 1 | 2014 | 512 | 0.100 |
Why?
|
Mental Health | 2 | 2023 | 3019 | 0.100 |
Why?
|
User-Computer Interface | 1 | 2017 | 1431 | 0.090 |
Why?
|
Educational Measurement | 1 | 2017 | 1210 | 0.090 |
Why?
|
Genetic Association Studies | 2 | 2018 | 2703 | 0.090 |
Why?
|
Insurance Claim Review | 1 | 2015 | 720 | 0.090 |
Why?
|
Social Adjustment | 1 | 2012 | 631 | 0.090 |
Why?
|
Nerve Growth Factors | 1 | 2012 | 574 | 0.090 |
Why?
|
Referral and Consultation | 1 | 2022 | 3528 | 0.080 |
Why?
|
Disability Evaluation | 1 | 2016 | 1827 | 0.080 |
Why?
|
Residence Characteristics | 1 | 2018 | 2050 | 0.080 |
Why?
|
Patient Satisfaction | 2 | 2021 | 3396 | 0.080 |
Why?
|
Magnetic Resonance Imaging | 8 | 2022 | 35421 | 0.080 |
Why?
|
Intelligence | 1 | 2012 | 920 | 0.080 |
Why?
|
Joint Diseases | 1 | 2011 | 480 | 0.070 |
Why?
|
Resilience, Psychological | 1 | 2014 | 676 | 0.070 |
Why?
|
Tuberous Sclerosis | 1 | 2015 | 1029 | 0.070 |
Why?
|
Quality Improvement | 1 | 2022 | 3749 | 0.070 |
Why?
|
Retrospective Studies | 7 | 2018 | 77449 | 0.070 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2014 | 2016 | 0.060 |
Why?
|
Scoliosis | 1 | 2011 | 725 | 0.060 |
Why?
|
Infant, Newborn | 2 | 2015 | 25625 | 0.060 |
Why?
|
Meningioma | 1 | 2013 | 1209 | 0.060 |
Why?
|
Socioeconomic Factors | 1 | 2017 | 7785 | 0.060 |
Why?
|
Autistic Disorder | 1 | 2012 | 1185 | 0.060 |
Why?
|
Cross-Sectional Studies | 2 | 2022 | 25043 | 0.060 |
Why?
|
Radiography | 1 | 2014 | 7023 | 0.050 |
Why?
|
Brain Neoplasms | 2 | 2015 | 8863 | 0.050 |
Why?
|
Pain | 2 | 2016 | 4986 | 0.050 |
Why?
|
Gulf War | 1 | 2021 | 29 | 0.050 |
Why?
|
Cafe-au-Lait Spots | 1 | 2021 | 18 | 0.050 |
Why?
|
Prospective Studies | 4 | 2022 | 53288 | 0.050 |
Why?
|
Child, Preschool | 4 | 2016 | 41006 | 0.050 |
Why?
|
Cohort Studies | 4 | 2018 | 40561 | 0.040 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2014 | 3658 | 0.040 |
Why?
|
Photography | 1 | 2021 | 520 | 0.040 |
Why?
|
Follow-Up Studies | 5 | 2022 | 39050 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2014 | 6234 | 0.040 |
Why?
|
Epilepsy | 1 | 2012 | 3310 | 0.040 |
Why?
|
Drug Administration Schedule | 2 | 2016 | 4933 | 0.040 |
Why?
|
Depression | 1 | 2016 | 7766 | 0.040 |
Why?
|
Pregnancy | 2 | 2015 | 29144 | 0.030 |
Why?
|
Genetic Testing | 2 | 2021 | 3444 | 0.030 |
Why?
|
Aged, 80 and over | 3 | 2021 | 57776 | 0.030 |
Why?
|
Analgesics | 1 | 2022 | 1040 | 0.030 |
Why?
|
Feasibility Studies | 2 | 2016 | 5078 | 0.030 |
Why?
|
Europe | 1 | 2021 | 3339 | 0.030 |
Why?
|
Factor Analysis, Statistical | 1 | 2017 | 977 | 0.030 |
Why?
|
Compassionate Use Trials | 1 | 2014 | 46 | 0.030 |
Why?
|
Videoconferencing | 1 | 2016 | 195 | 0.030 |
Why?
|
Mutation | 2 | 2016 | 29786 | 0.030 |
Why?
|
Obstetric Labor, Premature | 1 | 2015 | 279 | 0.030 |
Why?
|
Treatment Outcome | 5 | 2022 | 63114 | 0.030 |
Why?
|
Infant | 1 | 2015 | 35136 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2015 | 546 | 0.030 |
Why?
|
Single-Blind Method | 1 | 2016 | 1590 | 0.030 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 2282 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2015 | 552 | 0.030 |
Why?
|
Phenotype | 3 | 2016 | 16365 | 0.030 |
Why?
|
Psychometrics | 1 | 2021 | 3002 | 0.030 |
Why?
|
Pandemics | 2 | 2023 | 8388 | 0.030 |
Why?
|
Audiometry, Pure-Tone | 1 | 2012 | 204 | 0.030 |
Why?
|
Principal Component Analysis | 1 | 2015 | 940 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2013 | 3508 | 0.020 |
Why?
|
Review Literature as Topic | 1 | 2013 | 336 | 0.020 |
Why?
|
Proteinuria | 1 | 2014 | 658 | 0.020 |
Why?
|
Boston | 2 | 2015 | 9313 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2022 | 10943 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2022 | 12026 | 0.020 |
Why?
|
Perception | 1 | 2015 | 1198 | 0.020 |
Why?
|
Incidental Findings | 1 | 2011 | 689 | 0.020 |
Why?
|
Disease Progression | 2 | 2014 | 13284 | 0.020 |
Why?
|
Cesarean Section | 1 | 2015 | 1365 | 0.020 |
Why?
|
Disease Management | 1 | 2017 | 2459 | 0.020 |
Why?
|
Population Surveillance | 1 | 2016 | 2616 | 0.020 |
Why?
|
Pre-Eclampsia | 1 | 2015 | 1200 | 0.020 |
Why?
|
Patient-Centered Care | 1 | 2014 | 1439 | 0.010 |
Why?
|
Prognosis | 2 | 2015 | 29063 | 0.010 |
Why?
|
Adaptation, Psychological | 1 | 2014 | 2576 | 0.010 |
Why?
|
Regression Analysis | 1 | 2013 | 6459 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2021 | 19905 | 0.010 |
Why?
|
Patient Acceptance of Health Care | 1 | 2016 | 3022 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 2013 | 2635 | 0.010 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2012 | 6038 | 0.010 |
Why?
|
Risk Assessment | 2 | 2015 | 23338 | 0.010 |
Why?
|
Risk Factors | 3 | 2015 | 72290 | 0.010 |
Why?
|
Databases, Factual | 1 | 2016 | 7729 | 0.010 |
Why?
|
Pilot Projects | 1 | 2014 | 8324 | 0.010 |
Why?
|
Registries | 1 | 2016 | 8089 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2015 | 11031 | 0.010 |
Why?
|
Logistic Models | 1 | 2015 | 13408 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2013 | 11366 | 0.010 |
Why?
|
Software | 1 | 2013 | 4443 | 0.010 |
Why?
|
Sex Factors | 1 | 2012 | 10397 | 0.010 |
Why?
|
Transcription Factors | 1 | 2018 | 12208 | 0.010 |
Why?
|
Comorbidity | 1 | 2011 | 10388 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2013 | 8949 | 0.010 |
Why?
|
Hospitalization | 1 | 2015 | 10262 | 0.010 |
Why?
|
Age Factors | 1 | 2012 | 18370 | 0.010 |
Why?
|
Prevalence | 1 | 2011 | 15226 | 0.010 |
Why?
|
Hypertension | 1 | 2014 | 8480 | 0.010 |
Why?
|
Time Factors | 1 | 2013 | 40075 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2015 | 15165 | 0.010 |
Why?
|